Market Overview

UPDATE: Citigroup Initiates Supernus Pharmaceuticals at Neutral; Fully Valued

Share:
Related
Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug
18 Biggest Mid-Day Gainers For Thursday
This Top Biotech Stock Remains Just Within Buy Range (Investor's Business Daily)

Citigroup initiated coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Neutral/High Risk rating and a $14 price target.

Citigroup noted, "We recognize the potential opportunities for SUPN's extended release epilepsy drugs Oxtellar XR (SPN-804) and Trokendi XR (Extended release Topamax). However believe the company is currently fairly valued based on the risk associated with the company's commercial execution to recognize the potential value of these programs. Physician feedback has highlighted the importance of impact of early launch efforts/impact on long-term potential for an epilepsy product."

Supernus Pharmaceuticals closed at $11.39 on Monday.

Latest Ratings for SUPN

DateFirmActionFromTo
Jun 2017PiperJaffrayUpgradesNeutralOverweight
Dec 2016Cantor FitzgeraldInitiates Coverage OnOverweight
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for SUPN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SUPN)

View Comments and Join the Discussion!